Recombinant Human GITR / TNFRSF18 Protein, His-Tag, 100µg

Background
Glucocorticoid-induced TNFR-related protein (GITR) is also known as Tumor necrosis factor receptor superfamily member 18 (TNFRSF18), activation-inducible TNFR family receptor (AITR), CD antigen CD357, which is a member of the tumor necrosis factor receptor (TNF-R) superfamily. GITR is receptor for TNFSF18, which seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. GITR also mediated NF-kappa-B activation via the TRAF2/NIK pathway.

Source
Recombinant Human GITR, His Tag (GIR-H5228) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Glu 161 (Accession # Q9Y5U5-1).
Predicted N-terminus: Gln 26

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 16.4 kDa. The protein migrates as 20-25 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>92% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model"
Yeong Song, Guk Han, Kim et al
Radiother Oncol (2023)
(2) "Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4"
Alsalloum, Shevchenko, Fisher et al
Int J Mol Sci (2023) 24 (20)
(3) "APR-246 increases tumor antigenicity independent of p53"
Michels, Venkatesh, Liu et al
Life Sci Alliance (2024) 7 (1)
Showing 1-3 of 1056 papers.